Biopharma Opportunities and Obligations
Gain insights on the value of public/private partnership in developing platforms for pandemic preparedness.
Increasing biopharma agility and flexibility
Resilient biomanufacturing is key to support robust, flexible and agile global biopharma supply chains prepared for rapid response and new modality adaptation. Learn how government support, increased industry collaboration, training and education advancements, and onshore biomanufacturing capacity investments all position biopharma for future biomanufacturing resilience.
Addressing new, unknown modalities
Securing the capacity necessary to support production of innovative therapies is an essential part of bringing them to market. Understand how to meet the unique needs of different modalities across entire workflows, increase operational efficiency and flexibility, and protect stability of molecules throughout production.
Bioprocess capacity solutions
Adapt to evolving biomanufacturing demands and rapid capacity needs with modular facilities and integrated, flexible manufacturing trains. Innovate and expand your production environment and workflow needs.
Resource center
Featured article
Building biopharma resilience through education and training
Continuing education and additional job training are key to bridge biopharma skills gaps, grow talent and provide resilient biopharmaceutical supply chains. Read this article for new insights from NIBRT, Teesside University’s National Horizons Centre (NHC) and other leaders to learn how new approaches for talent sourcing and to fill specialized-skills gaps can grow biomanufacturing resilience.
Popular articles
Bridging the skills gap in biopharma
Understand how you can ensure your staff is up to date on today’s complex bioprocessing techniques and technologies.
Standardized approaches to biomanufacturing
Lower costs, improve outcomes and alter the landscape of the global pharmaceutical market.
Viral vector manufacturing: the key to the success of gene therapy
Understand current challenges and trends influencing design considerations for viral vector manufacturing facilities and how they can impact companies developing cell and gene therapies.
Staying flexible in biomanufacturing with optionality
The biopharma industry offers big rewards – but it poses big risks, too. Rather than fearing the unknown, the concept of optionality can help you better manage it.
mRNA production
Increasing mRNA capabilities and capacity for growing market needs.
Viral vector therapies
Designing agile manufacturing with an integrated drug substance/drug product ecosystem.